Ciclesonide

Ciclesonide
	File:Ciclesonide.svg
	File:Ciclesonide ball-and-stick animation.gif
Systematic (IUPAC) name
	2-[(1S, 2S, 4R, 8S, 9S,11S, 12S, 13R)-6-cyclohexyl-11-hydroxy-9, 13-dimethyl-16-oxo-5, 7-dioxapentacyclo [10.8.0.02,9.04, 8.013,18] icosa-14, 17-dien-8-yl]- 2-oxoethyl 2-methylpropanoate
Clinical data
AHFS/Drugs.com	monograph
MedlinePlus	a607008
Pregnancy; category	AU: B3 ; US: C (Risk not ruled out) ; ;
Legal status	AU: Prescription Only (S4) ; UK: Prescription-only (POM) ; US: ℞-only ;
Routes of; administration	nasal inhalation
Identifiers
CAS Registry Number	141845-82-1 7px
ATC code	R01AD13 R03BA08
PubChem	CID 6918155
DrugBank	DB01410 7px
ChemSpider	5293368 7px
UNII	S59502J185 7px
KEGG	D01703 7px
ChEMBL	CHEMBL1201164 7px
Synonyms	(11β, 16α)-16, 17-[[(R)-cyclohexylmethylene]bis(oxy)]-11-hydroxy-21- (2-methyl-1-oxopropoxy)- pregna-1, 4-diene-3, 20-dione
Chemical data
Formula	C32H44O7
Molecular mass	540.688 g/mol
	SMILES O=C(OCC(=O)[C@]25O[C@@H](O[C@@H]5C[C@H]1[C@H]4[C@H]([C@@H](O)C[C@@]12C)[C@]/3(/C=C\C(=O)\C=C\3CC4)C)C6CCCCC6)C(C)C;
	InChI InChI=1S/C32H44O7/c1-18(2)28(36)37-17-25(35)32-26(38-29(39-32)19-8-6-5-7-9-19)15-23-22-11-10-20-14-21(33)12-13-30(20,3)27(22)24(34)16-31(23,32)4/h12-14,18-19,22-24,26-27,29,34H,5-11,15-17H2,1-4H3/t22-,23-,24-,26+,27+,29+,30-,31-,32+/m0/s1 7px ; Key:LUKZNWIVRBCLON-GXOBDPJESA-N 7px ;
14px (what is this?) (verify)

</th></tr>

Ciclesonide is a glucocorticoid used to treat asthma and allergic rhinitis. It is marketed under the brand name Alvesco for asthma and Omnaris/Omniair for hay fever in the US and Canada. Phase 3 trials for the hay fever indication outside the US are ongoing.^[1] The drug was approved for adults and children 12 and over by the US Food and Drug Administration in October 2006.^[2] Side effects of the medication include headache, nosebleeds, and inflammation of the nose and throat linings.^[3]

References

^ "OMNARIS/OMNAIR". Products. Nycomed International Management GmbH. 2009. Retrieved 2009-07-30. ^{[dead link]}
^ "FDA NEWS RELEASE. FDA Approves New Treatment for Allergies.". Food and Drug Administration. 2006-10-23. Retrieved 2009-07-30.
^ Mutch, Elaine; Nave, Ruediger; McCracken, Nigel; Zech, Karl; Williams, Faith M. (2007). "The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue". Biochemical Pharmacology 73 (10): 1657–64. PMID 17331475. doi:10.1016/j.bcp.2007.01.031.

Rossi S (Ed.) (2006). Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook. ISBN 0-9757919-2-3

[1] "OMNARIS/OMNAIR". Products. Nycomed International Management GmbH. 2009. Retrieved 2009-07-30. ^{[dead link]}

[2] "FDA NEWS RELEASE. FDA Approves New Treatment for Allergies.". Food and Drug Administration. 2006-10-23. Retrieved 2009-07-30.

[mutch2007-3] Mutch, Elaine; Nave, Ruediger; McCracken, Nigel; Zech, Karl; Williams, Faith M. (2007). "The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue". Biochemical Pharmacology 73 (10): 1657–64. PMID 17331475. doi:10.1016/j.bcp.2007.01.031.

[1]

[2]

[3]

Search

Actions

Journals

Adverts

Frequent Links

Open Access Articles- Top Results for Ciclesonide

Ciclesonide

References